Search results
Showing 151 to 165 of 1165 results for criteria
Awaiting development Reference number: GID-TA11914 Expected publication date: TBC
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]
Awaiting development Reference number: GID-TA11935 Expected publication date: TBC
Awaiting development Reference number: GID-TA11933 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]
Awaiting development Reference number: GID-TA11928 Expected publication date: TBC
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]
Awaiting development Reference number: GID-TA11923 Expected publication date: TBC
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]
Awaiting development Reference number: GID-TA11954 Expected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC